Calcium channel blockers in cardiac failure

Progress in Cardiovascular Diseases

Volumn 41, Issue 3, 1998, Pages 191-206

  Mahon, N ^a   McKenna, W J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLDIGOXIN; ALDOSTERONE; AMLODIPINE; ATRIAL NATRIURETIC FACTOR; BENZOTHIAZEPINE DERIVATIVE; BEPRIDIL; CALCIUM; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DEOXYCORTICOSTERONE ACETATE; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDRALAZINE; ISOSORBIDE DINITRATE; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITROPRUSSIDE SODIUM; PHENYLALKYLAMINE; RENIN; TRANDOLAPRIL; UNINDEXED DRUG; VERAPAMIL;

ATHEROSCLEROSIS; BINDING SITE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MECHANISM; EXERCISE TOLERANCE; GENE EXPRESSION; HEART MUSCLE; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SARCOPLASMIC RETICULUM; SUBLINGUAL DRUG ADMINISTRATION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0032429656     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-0620(98)80055-8     Document Type: Article

References (179)

1. Ho K.K. Anderson K.M. Kannel W.B. Survival after the onset of congestive heart failure in Framingham Heart Study subjects Circulation 88 1993 107 115
2. Schwartz A. McKenna E. Vaghy P.L. Receptors for calcium antagonists Am J Cardiol 62 1988 3G 6G
3. Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation? Circulation 92 1995 1079 1082
4. Buring J.E. Glynn R.J. Hennekens C.H. Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested JAMA 274 1995 654 655
5. Pahor M. Guralnik J.M. Corti M.C. Long-term survival and use of antihypertensive medications in older persons J Am Geriatr Soc 43 1995 1191 1197
6. Horton R. Spinning the risks and benefits of calcium antagonists Lancet 346 1995 586 587
7. Kloner R.A. Nifedipine in ischemic heart disease Circulation 92 1995 1074 1078
8. Opie L.H. Messerli F.H. Nifedipine and mortality. Grave defects in the dossier Circulation 92 1995 1068 1073
9. Nayler W.G. Tissue Selectivity Nayler W.G. Calcium Antagonists 1988 Academic San Diego, CA 113 129
10. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum Am J Physiol 245 1983 C1 C14
11. Tanabe T. Beam K.G. Adams B.A. Regions of the skeletal muscle dihydropyridine receptor critical for excitation-contraction coupling Nature 346 1990 567 569
12. Catterall W.A. Structure and function of voltagesensitive ion channels Science 242 1988 50 61
13. McDonald T.F. Pelzer S. Trautwein W. Pelzer D.J. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells Physiol Rev 74 1994 365 507
14. Ferrari R. Major differences among the three classes of calcium antagonists Eur Heart J 18 suppl A 1997 A56 A70
15. Coraboeuf E. Nargeot J. Electrophysiology of human cardiac cells Cardiovasc Res 27 1993 1713 1725
16. Hagiwara N. Irisawa H. Kameyama M. Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells J Physiol 395 1988 233 253
17. Zhou Z. Lipsius S.L. T-type calcium current in latent pacemaker cells isolated from cat right atrium J Mol Cell Cardiol 26 1994 1211 1219
18. 2+ currents in compensated hypertrophy and heart failure Cardiovasc Res 37 1998 300 311
19. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes Circ Res 73 1993 777 782
20. Katz A.M. Calcium channel diversity in the cardiovascular system J Am Coll Cardiol 28 1996 522 529
21. Kalasz H. Watanabe T. Yabana H. Identification of 1,4-dihydropyridine binding domains within the primary structure of the alpha 1 subunit of the skeletal muscle L-type calciumchannel FEBS Lett 331 1993 177 181
22. Opie L.H. Buhler F.R. Fleckenstein A. International Society and Federation of Cardiology: Working Group on Classification of Calcium Antagonists for Cardiovascular Disease Am J Cardiol 60 1987 630 632
23. Varadi G. Mori Y. Mikala G. Schwartz A. Molecular determinants of Ca2+ channel function and drug action Trends Pharmacol Sci 16 1995 43 49
24. Rampe D. Triggle D.J. New ligands for L-type Ca2+ channels Trends Pharmacol Sci 11 1990 112 115
25. Thomas G. Gross R. Schramm M. Calcium channel modulation: Ability to inhibit or promote calcium influx resides in the same dihydropyridine molecule J Cardiovasc Pharmacol 6 1984 1170 1176
26. Ferrari R. Raddino R. Ceconi C. Prolonged protective effect of the calcium antagonist anipamil on the ischemic reperfused rabbit myocardium: Comparison with verapamil Cardiovasc Drug Ther 3 1989 403 412
27. Ferrari R. Boraso A. Condorelli E. Protective effects of gallopamil against ischemia and reperfusion damage Zeitschrift fur Kardiologie 78 suppl 5 1989 1 11
28. 174P Bolton T.B. Kitamura K. Morel N. Use dependent effects of calcium entry blocking drug on the electrical and mechanical activities of guinea-pig taenia caeci Br J Pharmacol 78 1983
29. Reid J.L. Meredith P.A. Donnelly R. Elliott H.L. Pharmacokinetics of calcium antagonists J Cardiovasc Pharmacol 12 suppl 7 1988 S22 S26
30. (suppl) Myers M.G. Dihydropyridine calcium antagonists and the trough: peak ratio: focus on adverse effects J Hypertens 12 1994 S73 S76
31. Santana L.F. Cheng H. Gomez A.M. Relation between the sarcolemmal Ca2+ current and Ca2+ sparks and local control theories for cardiac excitationcontraction coupling Circ Res 78 1996 166 171
32. Cheng H. Lederer W.J. Cannell M.B. Calcium sparks: Elementary events underlying excitation-contraction coupling in heart muscle Science 262 1993 740 744
33. Flesch M. Schwinger R.H. Schiffer F. Evidence for functional relevance of an enhanced expression of the Na(+)-Ca2+ exchanger in failing human myocardium Circulation 94 1996 992 1002
34. Studer R. Reinecke H. Bilger J. Gene expression of the cardiac Na(+)-Ca2+ exchanger in endstage human heart failure Circ Res 75 1994 443 453
35. Reinecke H. Studer R. Vetter R. Cardiac Na+/Ca2+ exchange activity in patients with endstage heart failure Cardiovasc Res 31 1996 48 54
36. Norgaard A. Bagger J.P. Bjerregaard P. Relation of left ventricular function and Na,K-pump concentration in suspected idiopathic dilated cardiomyopathy Am J Cardiol 61 1988 1312 1315
37. Schmidt T.A. Allen P.D. Colucci W.S. No adaptation to digitalization as evaluated by digitalis receptor (Na,K-ATPase) quantification in explanted hearts from donors without heartdisease and from digitalized recipients with end-stage heart failure Am J Cardiol 71 1993 110 114
38. Schmidt T.A. Holm-Nielsen P. Kjeldsen K. No upregulation of digitalis glycoside receptor (Na,K-ATPase) concentration in human heart left ventricle samples obtained at necropsy after longterm digitalisation Cardiovasc Res 25 1991 684 691
39. Ouadid H. Seguin J. Richard S. Properties and modulation of Ca channels in adult human atrial cells J Mol Cell Cardiol 23 1991 41 54
40. Le Grand B. Hatem S. Deroubaix E. Calcium current depression in isolated human atrial myocytes after cessation of chronic treatment with calcium antagonists Circ Res 69 1991 292 300
41. Ouadid H. Albat B. Nargeot J. Calcium currents in diseased human cardiac cells J Cardiovasc Pharmacol 25 1995 282 291
42. Takahashi T. Allen P.D. Lacro R.V. Expression of dihydropyridine receptor (Ca2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure J Clin Invest 90 1992 927 935
43. [see comments] Beuckelmann D.J. Nabauer M. Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure Circulation 85 1992 1046 1055
44. Beuckelmann D.J. Erdmann E. Ca(2+)-currents and intracellular [Ca2+]i-transients in single ventricular myocytes isolated from terminally failing human myocardium Basic Res Cardiol 87 suppl 1 1992 235 243
45. Sainte Beuve C. Allen P.D. Dambrin G. Cardiac calcium release channel (ryanodine receptor) in control and cardiomyopathic human hearts: mRNA and protein contents are differentially regulated J Mol Cell Cardiol 29 1997 1237 1246
46. Go L.O. Moschella M.C. Watras J. Differential regulation of two types of intracellular calcium release channels during end-stage heart failure J Clin Invest 95 1995 888 894
47. Nimer L.R. Needleman D.H. Hamilton S.L. Effect of ryanodine on sarcoplasmic reticulum Ca2+ accumulation in nonfailing and failing human myocardium Circulation 92 1995 2504 2510
48. Brillantes A.M. Allen P. Takahashi T. Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-stage heart failure caused byischemic versus dilated cardiomyopathy Circ Res 71 1992 18 26
49. D'Agnolo A. Luciani G.B. Mazzucco A. Contractile properties and Ca2+ release activity of the sarcoplasmic reticulum in dilated cardiomyopathy Circulation 85 1992 518 525
50. Schumacher C. Konigs B. Sigmund M. The ryanodine binding sarcoplasmic reticulum calcium release channel in nonfailing and in failing human myocardium Naunyn-Schmiedebergs Arch Pharmacol 353 1995 80 85
51. Linck B. Boknik P. Eschenhagen T. Messenger RNA expression and immunological quantification of phospholamban and SR-Ca(2+)-ATPase in failing and nonfailing human hearts Cardiovasc Res 31 1996 625 632
52. Schwinger R.H. Bohm M. Schmidt U. Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts Circulation 92 1995 3220 3228
53. Mercadier J.J. Lompre A.M. Duc P. Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure J Clin Invest 85 1990 305 309
54. Gwathmey J.K. Copelas L. MacKinnon R. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure Circ Res 61 1987 70 76
55. Beuckelmann D.J. Nabauer M. Erdmann E. Alterations of K+ currents in isolated human ventricular myocytes from patients with terminal heart failure Circ Res 73 1993 379 385
56. Koumi S. Backer C.L. Arentzen C.E. Sato R. betaAdrenergic modulation of the inwardly rectifying potassium channel in isolated human ventricular myo cytes. Alteration in channel response tobetaadrenergic stimulation in failing human hearts J Clin Invest 96 1995 2870 2881
57. Koumi S. Backer C.L. Arentzen C.E. Characterization of inwardly rectifying K+ channel in human cardiac myocytes. Alterations in channel behavior in myocytes isolated from patients with idiopathic dilated cardiomyopathy Circulation 92 1995 164 174
58. Hasenfuss G. Reinecke H. Studer R. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium Circ Res 75 1994 434 442
59. Limas C.J. Olivari M.T. Goldenberg I.F. Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy Cardiovasc Res 21 1987 601 605
60. Movsesian M.A. Karimi M. Green K. Jones L.R. Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium Circulation 90 1994 653 657
61. Meyer M. Schillinger W. Pieske B. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy Circulation 92 1995 778 784
62. Wickenden A.D. Kaprielian R. Kassiri Z. The role of action potential prolongation and altered intracellular calcium handling in the pathogenesis of heart failure Cardiovasc Res 37 1998 312 323
63. Finkbeiner S. Greenberg M.E. Ca(2+)-dependent routes to Ras: Mechanisms for neuronal survival, differentiation, and plasticity? Neuron 16 1996 233 236
64. Schmidt J. Depolarization-transcription coupling in excitable cells Rev Physiol Biochem Pharmacol 127 1996 251 279
65. Levitan E.S. Gealy R. Trimmer J.S. Takimoto K. Membrane depolarization inhibits Kv1.5 voltagegated K+ channel gene transcription and protein expression in pituitary cells J Biol Chem 270 1995 6036 6041
66. Muller A. Zuidwijk M.J. Simonides W.S. van Hardeveld C. Modulation of SERCA2 expression by thyroid hormone and norepinephrine in cardiocytes: Role of contractility Am J Physiol 272 1997 H1876 H1885
67. Grohe C. Nouskas J. Vetter H. Neyses L. Effects of nisoldipine on endothelin-1- and angiotensin II-induced immediate/early gene expression and protein synthesis in adult rat ventricularcardiomyocytes J Cardiovasc Pharmacol 24 1994 13 16
68. Ito H. Hirata Y. Hiroe M. Endothelin-1 induces hypertrophy with enhanced expression of musclespecific genes in cultured neonatal rat cardiomyocytes Circ Res 69 1991 209 215
69. Bogoyevitch M.A. Glennon P.E. Andersson M.B. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential roleof the cascade in the integration of two signaling pathways leading to myocyte hypertrophy J Biol Chem 269 1994 1110 1119
70. Sadoshima J. Izumo S. Signal transduction pathways of angiotensin II—induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospho lipid-derived second messengers Circ Res 73 1993 424 438
71. Yamazaki T. Tobe K. Hoh E. Mechanical loading activates mitogen-activated protein kinase and S6 peptide kinase in cultured rat cardiac myocytes J Biol Chem 268 1993 12069 12076
72. Bogoyevitch M.A. Glennon P.E. Sugden P.H. Endothelin-1, phorbol esters and phenylephrine stimulate MAP kinase activities in ventricular cardiomyocytes FEBS Lett 317 1993 271 275
73. Huang S. Maher V.M. McCormick J.J. Extracellular Ca2+ stimulates the activation of mitogen-activated protein kinase and cell growth in human fibroblasts Biochem J 310 1995 881 885
74. Chao T.S. Foster D.A. Rapp U.R. Rosner M.R. Differential Raf requirement for activation of mitogenactivated protein kinase by growth factors, phorbol esters, and calcium J Biol Chem 269 1994 7337 7341
75. Chao T.S. Byron K.L. Lee K.M. Activation of MAP kinases by calcium-dependent and calcium-independent pathways. Stimulation by thapsigargin and epidermal growth factor J Biol Chem 267 1992 19876 19883
76. Gruver C.L. DeMayo F. Goldstein M.A. Means A.R. Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice Endocrinology 133 1993 376 388
77. Allo S.N. Carl L.L. Morgan H.E. Acceleration of growth of cultured cardiomyocytes and translocation of protein kinase C Am J Physiol 263 1992 C319 C325
78. Henrich C.J. Simpson P.C. Differential acute and chronic response of protein kinase C in cultured neonatal rat heart myocytes to alpha 1-adrenergic and phorbol esterstimulation J Mol Cell Cardiol 20 1988 1081 1085
79. McConkey D.J. Orrenius S. The role of calcium in the regulation of apoptosis Biochem Biophys Res Commun 239 1997 357 366
80. [Review] Trump B.F. Berezesky I.K. The role of altered [Ca2+]i regulation in apoptosis, oncosis, and necrosis Biochim Biophys Acta 1313 1996 173 178
81. Kajstura J. Cigola E. Malhotra A. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro J Mol Cell Cardiol 29 1997 859 870
82. Feron O. Octave J.N. Christen M.O. Godfraind T. Quantification of two splicing events in the L-type calcium channel alpha-1 subunit of intestinal smooth muscle and other tissues Eur J Biochem 222 1994 195 202
83. Kung C.F. Tschudi M.R. Noll G. Differential effects of the calcium antagonist mibefradil in epicardial and intramyocardial coronary arteries J Cardiovasc Pharmacol 26 1995 312 318
84. Tschudi M.R. Criscione L. Novosel D. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats Circulation 89 1994 2212 2218
85. Henry P.D. Bentley K.I. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine J Clin Invest 68 1981 1366 1369
86. Goto K. Kasuya Y. Matsuki N. Endothelin activates the dihydropyridine-sensitive, voltagedependent Ca2+ channel in vascular smooth muscle Proc Natl Acad Sci USA 86 1989 3915 3918
87. Godfraind T. Mennig D. Morel N. Wibo M. Effect of endothelin-1 on calcium channel gating by agonists in vascular smooth muscle J Cardiovasc Pharmacol 13 suppl 5 1989 S112 S117
88. Yang Z.H. Richard V. von Segesser L. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation 82 1990 188 195
89. Luscher T.F. Wenzel R.R. Moreau P. Takase H. Vascular protective effects of ACE inhibitors and calcium antagonists: Theoretical basis for a combination therapy in hypertension and other cardiovascular diseases Cardiovasc Drug Ther 9 suppl 3 1995 509 523
90. Yang Z. Noll G. Luscher T.F. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derivedgrowth factor Circulation 88 1993 832 836
91. Rosenfeld M.E. Ross R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hype rcholesterolemic fat-fed rabbits Arteriosclerosis 10 1990 680 687
92. Napoli C. Chiariello M. Palumbo G. Ambrosio G. Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals Cardiovasc Drug Ther 10 1996 417 424
93. Loaldi A. Polese A. Montorsi P. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in anginapectoris Am J Cardiol 64 1989 433 439
94. Lichtlen P.R. Hugenholtz P.G. Rafflenbeul W. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators Lancet 335 1990 1109 1113
95. Waters D. Lesperance J. Francetich M. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis Circulation 82 1990 1940 1953
96. [see comments] Psaty B.M. Heckbert S.R. Koepsell T.D. The risk of myocardial infarction associated with antihypertensive drug therapies JAMA 274 1995 620 625
97. Furberg C.D. Psaty B.M. Meyer J.V. Nifedipine. Doserelated increase in mortality in patients with coronary heart disease Circulation 92 1995 1326 1331
98. Kostis J.B. Lacy C.R. Cosgrove N.M. Wilson A.C. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction Am Heart J 133 1997 550 557
99. Borhani N.O. Mercuri M. Borhani P.A. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial JAMA 276 1996 785 791
100. (abstr) Mason R.P. Cytoprotective properties of a long-acting calcium channel blocker Am J Hypertens 11 1998 254A
101. Mann D.L. Kent R.L. Parsons B. Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte Circulation 85 1992 790 804
102. Jiang J.P. Downing S.E. Catecholamine cardiomyopathy: Review and analysis of pathogenetic mechanisms Yale J Biol Med 63 1990 581 591
103. Bristow M.R. Port J.D. Hershberger R.E. The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure Eur Heart J 10 suppl B 1989 45 54
104. Lindpaintner K. Ganten D. The cardiac reninangiotensin system. An appraisal of present experimental and clinical evidence Circ Res 68 1991 905 921
105. Klein H.O. Ninio R. Oren V. The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment by equilibrium-gated radionuclide ventriculography Circulation 67 1983 101 110
106. Hof R.P. Comparison of cardiodepressant and vasodilator effects of PN 200-110 (isradipine), nifedipine and diltiazem in anesthetized rabbits Am J Cardiol 59 1987 37B 42B
107. Miller A.B. Conetta D.A. Bass T.A. Sublingual nifedipine: Acute effects in severe chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy Am J Cardiol 55 1985 1359 1362
108. Magorien R.D. Leier C.V. Kolibash A.J. Beneficial effects of nifedipine on rest and exercise myocardial energetics in patients with congestive heart failure Circulation 70 1984 884 890
109. Low R.I. Takeda P. Mason D.T. DeMaria A.N. The effects of calcium channel blocking agents on cardiovascular function Am J Cardiol 49 1982 547 553
110. Ludbrook P.A. Tiefenbrunn A.J. Sobel B.E. Influence of nifedipine left ventricular systolic and diastolic function. Relationships to manifestations of ischemia and congestive failure Am J Med 71 1981 683 692
111. Matsumoto S. Ito T. Sada T. Hemodynamic effects of nifedipine in congestive heart failure Am J Cardiol 46 1980 476 480
112. Klugmann S. Salvi A. Camerini F. Haemodynamic effects of nifedipine in heart failure Br Heart J 43 1980 440 446
113. Elkayam U. Weber L. Torkan B. Comparison of hemodynamic responses to nifedipine and nitroprus side in severe chronic congestive heart failure Am J Cardiol 53 1984 1321 1325
114. Elkayam U. Weber L. McKay C.R. Rahimtoola S.H. Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedi pine and direct-acting agonism with hydralazinein chronic refractory congestive heart failure Am J Cardiol 54 1984 126 131
115. Packer M. Lee W.H. Medina N. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction J Am Coll Cardiol 10 1987 1303 1311
116. Elkayam U. Roth A. Hsueh W. Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure Am Heart J 111 1986 1130 1138
117. Agostoni P.G. De Cesare N. Doria E. Afterload reduction: A comparison of captopril and nifedipine in dilated cardiomyopathy Br Heart J 55 1986 391 399
118. [see comments] Elkayam U. Amin J. Mehra A. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbidedinitrate and their combination in the treatment of chronic congestive heart failure Circulation 82 1990 1954 1961
119. [letter] Mandelzweig L. Goldbourt U. Reicher-Reiss H. Nifedipine does not improve survival in AMI patients without heart failure. The SPRINT Study Group Cardiovasc Drug Ther 7 1993 117 118
120. [Review] Charlap S. Frishman W.H. Calcium antagonists and heart failure Med Clin North Am 73 1989 339 359
121. Walsh R.W. Porter C.B. Starling M.R. O'Rourke R.A. Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure J Am Coll Cardiol 3 1984 1044 1050
122. Kulick D.L. McIntosh N. Campese V.M. Central and renal hemodynamic effects and hormonal response to diltiazem in severe congestive heart failure Am J Cardiol 59 1987 1138 1143
123. Heywood J.T. Graham B. Marais G.E. Jutzy K.R. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure Am J Cardiol 67 1991 1150 1152
124. Roth A. Harrison E. Mitani G. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation Circulation 73 1986 316 324
125. FiguIla H.R. Rechenberg J.V. Wiegand V. Beneficial effects of long-term diltiazem treatment in dilated cardiomyopathy J Am Coll Cardiol 13 1989 653 658
126. Anonymous The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group N Engl J Med 319 1988 385 392
127. Goldstein R.E. Boccuzzi S.J. Cruess D. Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The AdverseExperience Committee; and the Multicenter Diltiazem Postinfarction Research Group Circulation 83 1991 52 60
128. Anonymous Secondary prevention with verapamil after myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction Am J Cardiol 66 1990 331 401
129. Anonymous Verapamil in acute myocardial infarction. Danish Multicenter Study Group on Verapamil in Myocardial Infarction Am J Cardiol 54 1984 24E 28E
130. Kiowski W. Erne P. Pfisterer M. Arterial vasodilator, systemic and coronary hemodynamic effects of nisoldipine in congestive heart failure secondary to ischemic or dilatedcardiomyopathy Am J Cardiol 59 1987 1118 1125
131. (abstr) Thier W. Roewer N. Minderjahn K.P. Haemodynamic effect of nisoldipine in chronic congestive heart failure J Am Coll Cardiol 3 1986 479
132. abstr Minderjahn K.I.P. Hanrath P. Bleifeld W. Hemodynamic effects of nisoldipine in chronic congestive heart failure Eur Heart J 4 suppl E 1993 26
133. Dei Cas L. Metra M. Ferrari R. Visioli O. Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemody namics, neurohumoral parameters,and functional capacity of patients with chronic heart failure Cardiovasc Drug Ther 7 1993 103 110
134. Lewis B.S. Makhoul N. Merdler A. Effect of nisoldipine on exercise performance in heart failure following myocardial infarction Cardiology 79 1991 39 45
135. Eichstaedt H. Effects of calcium antagonists in patients with coronary disease and heart failure: Left ventricular function following nisoldipine measured byradionuclide ventriculography J Cardiovasc Pharmacol 20 suppl 5 1992 S50 S54
136. Ryman K.S. Kubo S.H. Lystash J. Effect of nicardipine on rest and exercise hemodynamics in chronic congestive heart failure Am J Cardiol 58 1986 583 588
137. Lahiri A. Robinson C.W. Tovey J. Intravenous nicardipine in patients with chronic heart failure: a nuclear stethoscope study Postgrad Med J 60 suppl 4 1984 35 38
138. Lahiri A. Robinson C.W. Kohli R.S. Acute and chronic effects of nicardipine on systolic and diastolic left ventricular performance in patients with heart failure: a pilot study Clin Cardiol 9 1986 257 261
139. (abstr) Gheorghiade M. Hall V. Goldberg D. Long term clinical and neurohormonal effects of nicardipine in patients with severe heart failure on maintenance therapy with angiotensinconverting enzyme inhibitors J Am Coll Cardiol 17 1991 274A
140. Cheng C.P. Igarashi Y. Pettersson K. Little W.C. Effect of felodipine on left ventricular performance in conscious dogs: assessment by left ventricular pressure volume analysis J Pharmacol Exp Ther 257 1991 163 169
141. Culling W. Ruttley M.S. Sheridan D.J. Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease Br Heart J 52 1984 431 434
142. Binetti G. Pancaldi S. Giovanelli N. Hemodynamic effects of felodipine in congestive heart failure Cardiovasc Drug Ther 1 1987 161 167
143. Timmis A.D. Campbell S. Monaghan M.J. Acute haemodynamic and metabolic effects of felodipine in congestive heart failure Br Heart J 51 1984 445 451
144. Kassis E. Amtorp O. Long-term clinical, haemodynamic, angiographic, and neurohumoral responses to vasodilation with felodipine in patients with chronic congestive heart failure J Cardiovasc Pharmacol 15 1990 347 352
145. Dunselman P.H. Kuntze C.E. van Bruggen A. Efficacy of felodipine in congestive heart failure Eur Heart J 10 1989 354 364
146. Kassis E. Amtrop O. Skagen K. Sympathetic reflex control of subcutaneous blood flow in patients with congestive heart failure Clin Sci 70 1986 513 522
147. Goldsmith S.R. Effect of amlodipine and felodipine on sympathetic activity and baroreflex function in normal humans Am J Hypertens 8 1995 902 908
148. Cohn J.N. Ziesche S. Smith R. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril:V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group Circulation 96 1997 856 863
149. Littler W.A. Sheridan D.J. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group Br Heart J 73 1995 428 433
150. Ohtsuka M. Ono T. Hiroi J. Comparison of the cardiovascular effect of FR34235, a new dihydropyridine, with other calcium antagonists J Cardiovasc Pharmacol 5 1983 1074 1082
151. Greenberg B. Siemienczuk D. Broudy D. Hemodynamic effects of PN 200-110 (isradipine) in congestive heart failure Am J Cardiol 59 1987 70B 74B
152. Olivari M.T. Levine T.B. Cohn J.N. Acute hemodynamic effects of nitrendipine in chronic congestive heart failure J Cardiovasc Pharmacol 6 suppl 7 1984 S1002 S1005
153. de Vries R.J. Dunselman P.H. Chin Kon Sung U.G. Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in pa tients with mild to moderate chronic heart failure Heart 75 1996 159 164
154. Alpert J.S. Coumel P. Greeff K. Bepridil: A review of its pharmacology and clinical efficacy as an antianginal agent with anti-arrhythmic properties Pharmatherapeutica 4 1985 195 222
155. Tamari I. Borer J.S. Moses J.W. Hemodynamic assessment of intravenous bepridil administration in ischemic heart disease Am J Cardiol 55 1985 25C 29C
156. Josephson M.A. Mody T. Coyle K. Singh B.N. Effects on hemodynamics and left ventricular ejection fraction of intravenous bepridil for impaired left ventricular function secondary to coronaryartery disease Am J Cardiol 60 1987 44 49
157. Smith W.B. De Abate A.C. Gollub S.I.B. Beneficial long-term haemodynamic and clinical effects of amlodipine in chronic heart failure. Results of a multicen ter randomised, double blind, placebo controlled, dose ranging study Circulation 90 1994 602
158. Goldsmith S.R. Effect of amlodipine on norepinephrine kinetics and baroreflex function in patients with congestive heart failure Am Heart J 134 1997 13 19
159. 274A Packer M. Nicod P. Khanderia B.R. Randomized, multicenter, double blind, placebo controlled evaluation of amlodipine in patients with mild to moderate heart failure (abstr) J Am Coll Cardiol 17 1991
160. Packer M. O'Connor C.M. Ghali J.K. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlo dipine Survival Evaluation Study Group N Engl J Med 335 1996 1107 1114
161. Mohler E.R. III Sorensen L.C. Ghali J.K. Role of cytokines in the mechanism of action of amlodipine: The PRAISE Heart Failure Trial. Prospective Ran domized Amlodipine Survival Evaluation J Am Coll Cardiol 30 1997 35 41
162. Fang L.M. Osterrieder W. Potential-dependent inhibition of cardiac Ca2+ inward currents by Ro 40-5967 and verapamil: relation to negative inotropy Eur J Pharmacol 196 1991 205 207
163. [Review] Nelson M.T. Patlak J.B. Worley J.F. Standen N.B. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone Am J Physiol 259 1990 C3 C18
164. Clozel J.P. Veniant M. Osterrieder W. The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropiceffects of verapamil in normal and failing rat hearts Cardiovasc Drug Ther 4 1990 731 736
165. Schmitt R. Clozel J.P. Iberg N. Buhler F.R. Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel Arterioscler Thromb Vasc Biol 15 1995 1161 1165
166. Schmitt R. Clozel J.P. Iberg N. Buhler F.R. Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition Cardiovasc Drug Ther 10 1996 101 105
167. Gray G.A. Clozel M. Clozel J.P. Baumgartner H.R. Effects of calcium channel blockade on the aortic intima in spontaneously hypertensive rats Hypertension 22 1993 569 576
168. Massie B.M. Mibefradil: A selective T-type calcium antagonist Am J Cardiol 80 1997 231 321
169. Mulder P. Richard V. Compagnon P. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure J Am Coll Cardiol 29 1997 416 421
170. Ezzaher A. Houda Bouanani N. Su J.B. Increased negative inotropic effect of calciumchannel blockers in hypertrophied and failing rabbit heart J Pharmacol Exp Ther 257 1991 466 471
171. Investigational Drug Brochure Ro 40-5967 (calcium antagonist) January 1992 and addendum to the Investigational Drug Brochure (4th version, January 1992) of Ro 40-5967 (calcium antagonist) January 1993
172. Rousseau M.F. Hayashida W. van Eyll C. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction J Am Coll Cardiol 28 1996 972 979
173. Cohn J.N. Johnson G. Ziesche S. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N Engl J Med 325 1991 303 310
174. Hansen J.F. Hagerup L. Sigurd B. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandol april alone. Danish Verapamil Infarction Trial (DAVIT) Study Group Am J Cardiol 79 1997 738 741
175. Vasan R.S. Benjamin E.J. Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective J Am Coll Cardiol 26 1995 1565 1574
176. Rihal C.S. Nishimura R.A. Hatle L.K. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis Circulation 90 1994 2772 2779
177. Anonymous Improved diastolic function with the calcium antagonist nisoldipine (coat-core) in patients post myocardial infarction: results of the DEFIANT study. Doppler Flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy Eur Heart J 13 1992 1496 1505
178. Anonymous Doppler flow and echocardiography in functional cardiac insufficiency: Assessment of nisoldipine therapy. Results of the DEFIANT-II Study. The DEFIANT-II Research Group Eur Heart J 18 1997 31 40
179. Setaro J.F. Zaret B.L. Schulman D.S. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance Am J Cardiol 66 1990 981 986